Epidermal growth factor receptor mutation in gastric cancer

Aims: Epidermal growth factor receptor (EGFR) and Kirsten-RAS (KRAS) mutations have been identified as predictors of response to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer. We aimed to screen the mutations of both genes in gastric carcinoma to detect the suitability of EGFR TKIs for patients with gastric carcinoma. Methods: We screened EGFR mutation in exons 19–21 and KRAS mutation in exon 2 in 58 gastric adenocarcinomas from China using high resolution melting analysis (HRMA). Positive samples were confirmed by DNA sequencing. Results: Three EGFR missense mutations (5.2%) and 22 single nucleotide polymorphisms (SNP, Q787Q, 37.9%) were identified. To our knowledge, we report for the first time three mutation patterns of EGFR, Y801C, L858R and G863D, in gastric carcinoma. Two samples with EGFR mutation were mucinous adenocarcinoma. These three samples were collected from male patients aged over 75 years old. The frequency of KRAS mutation was 10.3% (6/58). The exclusiveness of EGFR and KRAS mutations was proven for the first time in gastric cancer. Conclusions: Gastric carcinoma of the mucinous adenocarcinoma type collected from older male patients may harbour EGFR mutations. The small subset of gastric adenocarcinoma patients may respond to EGFR TKIs.

[1]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[2]  Teruhiko Yoshida,et al.  Epidermal Growth Factor Receptor Mutation Detection Using High-Resolution Melting Analysis Predicts Outcomes in Patients with Advanced Non–Small Cell Lung Cancer Treated with Gefitinib , 2007, Clinical Cancer Research.

[3]  C. Pirker,et al.  EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases , 2009, Clinical Cancer Research.

[4]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[5]  H. Sasano,et al.  Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification , 1994, Cancer.

[6]  A. Longatto-Filho,et al.  Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma , 2009, BMC Cancer.

[7]  J. Siegfried,et al.  Prognostic value of specific KRAS mutations in lung adenocarcinomas. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[8]  E. Shpall,et al.  Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Mayumi Ono,et al.  Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas , 2005, Clinical Cancer Research.

[10]  Y. Jeon,et al.  EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number , 2008, Histopathology.

[11]  Hai-sheng Zhou,et al.  Gefitinib-Sensitive Mutations of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[12]  G. Fleuren,et al.  KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. , 1988, Nucleic acids research.

[13]  J. Minna,et al.  Inhibition of EGFR Signaling: All Mutations Are Not Created Equal , 2005, PLoS medicine.

[14]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[15]  S. Toyooka,et al.  Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib‐resistance in cells carrying EGFR mutation , 2007, Cancer science.

[16]  M. Agostini,et al.  Epidermal growth factor receptor (EGFR): mutational and protein expression analysis in gastric cancer. , 2006, Anticancer research.

[17]  C. Wittwer,et al.  Enrichment and detection of rare alleles by means of snapback primers and rapid-cycle PCR. , 2010, Clinical chemistry.

[18]  C. Fenoglio-Preiser,et al.  Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[20]  J. Fraumeni,et al.  Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. , 1995, Cancer research.

[21]  K. Mimori,et al.  The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers , 2006, Journal of surgical oncology.

[22]  T. Chou,et al.  Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[23]  Zhi-Min Liu,et al.  Mutation detection of KRAS by high-resolution melting analysis in Chinese with gastric cancer. , 2009, Oncology reports.

[24]  J. Haerting,et al.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Y. Bang,et al.  Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment. , 2008, Lung cancer.

[26]  A. Martín,et al.  Clinical Significance of the Epidermal Growth Factor Receptor and HER2 Receptor in Resectable Gastric Cancer , 2003, Annals of Surgical Oncology.

[27]  A. Børresen-Dale,et al.  Ki-ras mutations and prognosis in colorectal cancer. , 1998, European journal of cancer.

[28]  R. Seruca,et al.  Bmc Cancer Epidermal Growth Factor Receptor Structural Alterations in Gastric Cancer , 2022 .